Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors

• Published in: International journal of hematology Vol. 114; no. 5; pp. 572 - 579
• Main Authors: Ueda, Tatsuki, Kaneko, Shin
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.11.2021; Springer Nature B.V
• Subjects: Animals; Antigens; Antigens, Neoplasm - immunology; Cancer immunotherapy; Chimeric antigen receptors; Clinical Studies as Topic; Clinical trials; Combined Modality Therapy; Drug Evaluation, Preclinical; Gene Expression; Genetic Engineering; Hematology; Humans; Immune system; Immunotherapy; Immunotherapy, Adoptive - adverse effects; Immunotherapy, Adoptive - methods; Induced Pluripotent Stem Cells - cytology; Induced Pluripotent Stem Cells - metabolism; Killer Cells, Natural - cytology; Killer Cells, Natural - immunology; Killer Cells, Natural - metabolism; Medicine; Medicine & Public Health; Natural killer cells; Neoplasms - etiology; Neoplasms - therapy; Oncology; Pluripotency; Product safety; Prognosis; Progress in Hematology; Quality control; Receptors; Receptors, Chimeric Antigen - genetics; Receptors, Chimeric Antigen - immunology; Solid tumors; Stem cells; Treatment Outcome; Tumors; Natural killer cell; Induced pluripotent stem cell; Chimeric antigen receptor; Immunotherapy
• ISSN: 0925-5710; 1865-3774; 1865-3774
• DOI: 10.1007/s12185-020-02951-5

The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, regarding efficacy, safety, and producibility. In this review, we have described the characteristics of natural killer (NK) cells from multiple cell sources, including pluripotent stem cells, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells, and the current and planned clinical trials of CAR-modified induced pluripotent stem cell-derived NK cells.